CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
批准号:
10328213
负责人:
Jerzy W Kupiec-Weglinski
金额:
$53.42万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
未结题
起止时间:
2017-08-01 至 2027-07-31
关键词:
AcuteAddressAdvocateAlternative SplicingAnti-Inflammatory AgentsAutophagocytosisBiological MarkersBiometryBiopsyBrain DeathCEACAM1Cardiac DeathCell Culture SystemCell DeathCellsClinicalClinical assessmentsComplementComplement component C1CryopreservationCytoprotectionDataExclusionExonsGenesGoldHepaticHepatic TissueHepatocyteHumanImmuneImpairmentInflammationInjuryInterventionLifeLiverLymphocyteMAP Kinase GeneMediatingMessenger RNAMucosal ImmunityMusMyelogenousNatural ImmunityNatural regenerationOperative Surgical ProceduresOrganOrgan DonorOrgan PreservationOrgan TransplantationOutcomePathway interactionsPatientsPhasePhenotypeProtein IsoformsRNA SplicingRecoveryRegulationRejuvenationReperfusion InjuryReportingResistanceResolutionSavingsSentinelSignal TransductionSterilityStressTissuesTransgenic MiceTransplantationTransplantation SurgeryVariantWaiting ListsWarm Ischemiabasecarcinoembryonic antigen-related cell adhesion moleculesclinically relevantend stage liver diseaseexperimental studyimmunoregulationimprovedimproved functioninginsightliver functionliver inflammationliver ischemialiver transplantationmacrophagemortalitymouse modelneutrophilnovelnovel therapeuticsp38 Mitogen Activated Protein Kinasepreservationpreventprogramsregenerativerepairedscreeningstandard of caresuccesssynergismtransplant model
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT 1 – SUMMARY/ABSTRACT
Project 1 competitive renewal addresses the unmet clinical and scientific needs to enhance donor liver supply
through organ “rejuvenation.” We reported that hepatic CEACAM1 (encoded by CC1 gene; CD66a) dictates
donor liver quality, and prevents early OLT injury in mice and humans. CC1 mRNA undergoes alternative splicing
(AS) to generate splice variants, characterized by the inclusion (CC1-L; long) or exclusion (CC1-S; short) of exon
7. Hypothesis: Hepatocyte CC1-S functions as a cytoprotective sentinel, while CC1-L in OLT-infiltrating recipient-
derived neutrophils, regulates liver IR-inflammation and fine-tunes its resolution.
Aim 1: Delineate mechanisms by which hepatic CC1-S isoform promotes cellular protection in IR-
stressed mouse OLT. Hypothesis: Antisense oligomer morpholinos (MOs)-enforced AS of hepatic CC1
generates CC1-S isoform in the donor mouse liver, which under the control of HIF-1α, stimulates cytoprotection
by blocking p-p38 (under cold IR-stress) while promoting GPX4 and targeting ferroptosis (under warm IR-stress).
Here, we will ascertain whether 1.1: CC1-AS accelerates otherwise impaired hepatic recovery in the acute and
the resolution phase of IR-inflammation. 1.2: CC1-S controls IRI-OLT by regulating hepatic cell death pathways.
1.3: CC1-S-mediated cytoprotection is controlled by HIF-1α signaling under warm vs. cold hepatic IR-stress.
Aim 2: Define mechanisms by which neutrophil CC1-L isoform exerts anti-inflammatory and
cytoprotective functions in IR-stressed mouse OLT. Hypothesis: Recipient CC1-L neutrophils counteract acute
IRI-OLT, and stimulate inflammation resolution by orchestrating N1/N2 polarization, with resultant liver
homeostatic/regenerative remodeling. We will study whether 2.1: Recipient CC1-L deficient immune cells
exacerbate hepatic IRI-OLT. 2.2: CC1-L polarizes N2 neutrophils to promote an anti-inflammatory phenotype/
improve OLT outcomes. 2.3: CC1-L proficient neutrophils polarize M2 macrophages/promote hepatic autophagy.
Aim 3: Elucidate mechanisms by which hepatic CC1-S isoform rejuvenates discarded human livers
subjected to normothermic machine preservation (NMP). Hypothesis: NMP, supplemented with HIF-1α – CC1-
S axis modifiers, improves the function of discarded human livers by mitigating ferroptosis while promoting
autophagy. We will incorporate the emerging NMP strategy with adjunctive CC1-intervention to assess whether
3.1: MOs-conditioned humanized CC1 transgenic mice (huCC1-Tg) mimic the effects of CC1-AS upon liver IR-
stress in normal mice but be translatable to the human liver. 3.2: CC1-S isoform synergizes with HIF-1α to
improve liver function. 3.3: CC1-S synergizes with HIF-1α to enhance cytoprotection in human livers.
Integration with PPG: Project 1 complements studies assessing homeostatic mechanisms in the
resolution of IRI-OLT in Project 2. Aim 1-2 in Project 1 will be validated by the screening of human OLT biopsies
to accelerate assessments of clinical innate immune phenotypes in Project 3. Project 1 is dependent on Core A
(Administrative), Core B (Mouse and Human OLT Surgery), and Core C (Computational and Biostatistics).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10101174
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10685284
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10472636
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
THE RELAXIN RECEPTOR GR/RXFP1 SIGNALING IN LIVER TRANSPLANT ISCHEMIA-REPERFUSION INJURY AND THE INFLAMMATION RESOLUTION
-
批准号:10268216
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immune Interface in Liver Ischemia-Reperfusion Injury
-
批准号:9975698
-
项目类别:
-
资助金额:$38.23万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9359428
-
项目类别:
-
资助金额:$168.58万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:10328210
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
CEACAM1 Alternative Splicing in Liver Ischemia-Reperfusion Injury
-
批准号:10622462
-
项目类别:
-
资助金额:$54.09万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:9975689
-
项目类别:
-
资助金额:$12.17万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9975685
-
项目类别:
-
资助金额:$167.45万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:9750602
-
项目类别:
-
资助金额:$168.08万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Admin Core
-
批准号:10622453
-
项目类别:
-
资助金额:$14.19万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:10622451
-
项目类别:
-
资助金额:$194.91万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Innate-Adaptive Immunoregulation in Liver Transplant Ischemia/Reperfusion Injury
-
批准号:10328209
-
项目类别:
-
资助金额:$194.13万
-
财政年份:2017
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
TIM-3 Negative Costimulation Signaling at the Innate-Adaptive Immune interface in Liver Transplant Ischemia-Reperfusion Injury
-
批准号:9198218
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2016
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
TIM-3 Negative Costimulation Signaling at the Innate-Adaptive Immune interface in Liver Transplant Ischemia-Reperfusion Injury
-
批准号:9005628
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2016
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Tim Costimulation in Liver Transplant Ischemia Injury
-
批准号:9029320
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2015
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
Tim Costimulation in Liver Transplant Ischemia Injury
-
批准号:8895119
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2015
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
HO1 ANDTLR4 IN LIVER ISCHEMIA/REPERFUSION INJURY IN TRANSPLANT RECIPIENTS
-
批准号:7808751
-
项目类别:
-
资助金额:$61.6万
-
财政年份:2009
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
HEME OXYGENASE-1 IN HEPATIC ISCHEMIA/REPERFUSION INJURY
-
批准号:6847822
-
项目类别:
-
资助金额:$33.55万
-
财政年份:2003
-
负责人:Jerzy W Kupiec-Weglinski
-
依托单位:
海外基金